

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:
LEARY, Kathryn, Doyle
Panitch Schwarze Jacobs & Nadel,
P.C.
One Commerce Square
22nd floor
2005 Market Street
Philadelphia, PA 19103-7086
ÉTATS-UNIS D'AMÉRIQUE

S. PTO
jc525 09/510268
02/22/00

Date of mailing (day/month/year) 04 March 1999 (04.03.99)		
Applicant's or agent's file reference 9596-61PC		
International application No. PCT/US98/17428	International filing date (day/month/year) 25 August 1998 (25.08.98)	Priority date (day/month/year) 25 August 1997 (25.08.97)
Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA et al.		

IMPORTANT NOTICE

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
AU,EP,JP,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:
CA

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 04 March 1999 (04.03.99) under No. WO 99/10013

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a **demand for international preliminary examination** must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the **national phase**, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer J. Zahra Telephone No. (41-22) 338.83.38
--	---

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 48/00, C07H 21/04, C12N 15/00, 15/11, 15/63, 15/85, 15/86		A1	(11) International Publication Number: WO 99/10013 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/US98/17428 (22) International Filing Date: 25 August 1998 (25.08.98)		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/057,201 25 August 1997 (25.08.97) US		Published <i>With international search report.</i>	
(71) Applicants (<i>for all designated States except US</i>): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US). MASSACHUSETTS GENERAL HOSPITAL [US/US]; Office of Technology Affairs, Building 149, Suite 1101, 13th Street, Charleston, MA 02129 (US).			
(72) Inventors; and (73) Inventors/Applicants (<i>for US only</i>): SWEENEY, H., Lee [US/US]; 1420 Walnut Street, Philadelphia, PA 19102 (US). ROSENTHAL, Nadia, A. [US/US]; 31 Brooks Street, Concord, MA (US).			
(74) Agents: LEARY, Kathryn, Doyle et al.; Panitch Schwarze Jacobs & Nadel, P.C., One Commerce Square, 22nd floor, 2005 Market Street, Philadelphia, PA 19103-7086 (US).			
(54) Title: THE USE OF INSULIN-LIKE GROWTH FACTOR-I IN MUSCLE			
(57) Abstract <p>The invention relates compositions and method for the use of insulin-like growth factor to enhance muscle mass and strength.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THE USE OF INSULIN-LIKE GROWTH FACTOR-I IN MUSCLE

FIELD OF THE INVENTION

5 The field of the invention is the use of insulin-like growth factor I to affect vertebrate muscle mass and strength.

BACKGROUND OF THE INVENTION

One of the primary consequences of aging leading to significantly impaired function in the elderly population is the loss of skeletal muscle strength and mass (Lamberts *et al.*, 1997, Science 278:419-424). Both muscle mass and strength decrease by up to one third in humans between the ages of 30 and 80 years (Tzankoff *et al.*, 1977, J. Appl. Physiol. 43:1001-1006). In addition, selective loss of the fastest, most powerful muscle fiber types (type IIb fibers) has been documented (Grimby *et al.*, 1982, Acta Physiol. Scand. 115:125-134). Similar age-related muscle alterations have 10 been observed in rats and mice, indicating that the trend is maintained in other mammalian species (Larrson and Edstrom, 1986, J. Neurol. Sci. 76:69-89; Brooks and Faulkner, 1988, J. Physiol. 404:71-82).

The loss of muscle mass and strength seen in aging mammals has given impetus to the search for compounds which may slow or reverse the process. One such 20 compound is insulin-like growth factor I (IGF-I), which is a peptide growth factor that is structurally related to proinsulin (Cohick *et al.*, 1993, Ann. Rev. Physiol. 55:131-153). IGF-I is critical in mediating the growth of muscle and other tissues (Florini *et al.*, 1996, Endocrine Reviews 17:481-517). Systemic administration of IGF-I results in increased muscle protein content and reduced protein degradation (Zdanowicz *et al.*, 25 1995, Endocrinology 136:4880-4886). Moreover, over-expression of IGF-I has been correlated with muscle hypertrophy in transgenic mouse lines (Coleman *et al.*, 1995, J.

Biol. Chem. 270:12109-12116). Further, addition of IGF-I to cultures of differentiating myocytes has been shown to result in hypertrophied myotubes (Florini *et al.*, 1989, Am. J. Physiol. 256:C701-711).

Previous studies have also suggested that there is a correlation between aging-related loss of muscle mass and strength and decreased levels of IGF-I. Lamberts *et al.* (1997, Science 278:419-424), demonstrated that with aging, there is a decrease in the production and activity of the growth hormone/IGF-I axis which leads to an increase in catabolic processes as exhibited by the age-related loss of muscle mass and strength. The prevention of muscle mass loss has been achieved in healthy individuals by growth hormone administration, and is associated with increases in IGF-I levels (Papadakis *et al.*, 1996, Ann. Intern. Med. 124:708-716).

The above-stated observations may also have important implications with regard to various muscular diseases. For example, aging-related changes in skeletal muscle mirror the early functional changes observed in muscular dystrophy, albeit on a much slower time scale. Just as in the muscles of old mice, the muscles of the mouse model of Duchenne muscular dystrophy (the mdx mouse) exhibit both decreased force per cross-sectional area and preferential loss of type IIb fibers (Petrof *et al.*, 1993, Am. J. Physiol. 265 (Cell Physiol. 34):C834-C841). These data suggest that IGF-I expression in dystrophic muscle, while not addressing the primary defect that results in increased susceptibility to injury (Petrof *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:3710-3714), may increase the rate of regeneration of the muscle and thereby tend to preserve muscle function.

Although the previous studies suggested that IGF-I may be useful in preserving muscle mass, these studies failed to demonstrate functional hypertrophy. That is, although there was an increase in muscle mass (*i.e.*, hypertrophy), there was no concomitant increase in specific muscle strength (defined as force per cross-sectional area). For example, Coleman *et al.* (1995, J. Biol. Chem. 270:12109-12116), demonstrated that the hypertrophic muscles of transgenic mice did not exhibit enhanced strength compared with muscle obtained from nontransgenic, but otherwise

identical animals. Indeed, the hypertrophied muscles of transgenic mice, although larger, were actually weaker than their non-transgenic counterparts (Leferovich *et al.*, 1995, J. Neurosci. 14:596-603). Thus, while there are clear indications that IGF-I may be involved in maintaining muscle mass in elderly individuals, these studies did not suggest that muscle function, as measured by strength, may be preserved by the administration of IGF-I.

To date, the only means for stimulating muscle hypertrophy involve the use of steroids which have deleterious side effects. Systemic administration of IGF-1 or growth hormone has proved ineffective and also may have deleterious side effects. Thus, there is a long-felt and unfilled need for the development of compositions and procedures for promoting growth of adult muscle, which growth also serves to enhance the overall strength of the muscle. The present invention satisfies this need.

SUMMARY OF THE INVENTION

The invention relates to a method of increasing vertebrate muscle mass and muscle strength. The method comprises administering a muscle enhancing dose of an isolated nucleic acid encoding Insulin-like Growth Factor I (IGF-I), or a modification or biologically active portion thereof, intramuscularly into a vertebrate, wherein the isolated nucleic acid is expressed in muscle cells, thereby increasing the muscle mass and the muscle strength in the muscle of the vertebrate.

In one aspect, the vertebrate is selected from a group consisting of rat, mouse, cat, dog, horse, cow, pig, sheep, goat, fish, bird, and human.

In a preferred embodiment, the vertebrate is a human.

In another preferred embodiment, the IGF-1 is of the same species as the vertebrate.

In another aspect, the isolated nucleic acid is contained within a virus vector.

In yet another aspect, the muscle enhancing dose ranges from between about 10^{10} to about 10^{12} recombinant virus vector particles per gram of muscle.

In yet another aspect, the method further comprises administering to the vertebrate fibroblast growth factor or neurotropin.

The invention also relates to an isolated nucleic acid comprising a vertebrate IGF-I coding region, or a modification or portion thereof, operably linked to a muscle specific promoter/regulatory region, wherein the IGF-I coding region is flanked on the 5' side by an SV40 intron sequence and wherein the IGF-I coding region is flanked on the 3' end by an SV40 polyadenylation signal sequence.

In one aspect, the muscle specific promoter/regulatory region is selected from a group consisting of the myosin light chain 1/3 promoter/enhancer, the skeletal 10 α -actin promoter, the muscle creatine kinase promoter/enhancer and a muscle specific troponin promoter.

In a preferred embodiment, the muscle specific troponin promoter is the fast troponin C promoter/enhancer.

In another preferred embodiment, the muscle specific 15 promoter/regulatory region is the myosin light chain 1/3 promoter/enhancer.

In another aspect, the muscle specific promoter/regulatory region further comprises an enhancer element operably linked to the IGF-I coding region.

In a preferred embodiment, the enhancer is the myosin light chain 1/3 enhancer.

20 Also included in the invention is a composition comprising a recombinant virus vector comprising an isolated nucleic acid comprising a vertebrate IGF-I coding region, or a modification or portion thereof, operably linked to a muscle specific promoter/regulatory region, wherein said IGF-I coding region is flanked on the 5' side by an SV40 intron sequence and wherein said IGF-I coding region is flanked on the 25 3' end by an SV40 polyadenylation signal sequence. The muscle specific promoter/regulatory region further comprises an enhancer element operably linked to the IGF-I coding region and the enhancer is the myosin light chain 1/3 enhancer.

In one aspect, the recombinant virus vector is selected from the group consisting of an adeno-associated virus, an adenovirus and a herpes simplex virus.

In a preferred embodiment, the recombinant virus vector is an adeno-associated virus.

Also included in the invention is a cell comprising an isolated nucleic acid comprising a vertebrate IGF-I coding region, or a modification or portion thereof, operably linked to a muscle specific promoter/regulatory region, wherein said IGF-I coding region is flanked on the 5' side by an SV40 intron sequence and wherein said IGF-I coding region is flanked on the 3' end by an SV40 polyadenylation signal sequence.

The invention further includes a cell comprising a recombinant virus vector comprising an isolated nucleic acid comprising a vertebrate IGF-I coding region, or a modification or portion thereof, operably linked to a muscle specific promoter/regulatory region, wherein said IGF-I coding region is flanked on the 5' side by an SV40 intron sequence and wherein said IGF-I coding region is flanked on the 3' end by an SV40 polyadenylation signal sequence. The muscle specific promoter/regulatory region further comprises an enhancer element operably linked to the IGF-I coding region and the enhancer is the myosin light chain 1/3 enhancer.

The invention additionally includes a kit for increasing muscle mass and muscle strength in a vertebrate. The kit comprises a muscle enhancing dose of an isolated nucleic acid comprising a vertebrate IGF-I coding region, or a modification or portion thereof, operably linked to a muscle specific promoter/regulatory region, wherein said IGF-I coding region is flanked on the 5' side by an SV40 intron sequence and wherein said IGF-I coding region is flanked on the 3' end by an SV40 polyadenylation signal sequence, wherein the isolated nucleic acid is expressed in vertebrate muscle cells, and wherein the kit further comprises an applicator for delivering the muscle enhancing dose, and instructions for the use of the kit.

Also included in the invention is a non-human transgenic vertebrate animal comprising an isolated nucleic acid encoding IGF-I, or a modification or biologically active portion thereof.

In one aspect, the IGF-1 is operably linked to a muscle specific promoter/regulatory sequence at the 5' end of the IGF-1 and a polyadenylation termination signal at the 3' end of the IGF-1.

In another aspect, the muscle specific promoter/regulatory sequence is selected from the group consisting of the myosin light chain 1/3 promoter/enhancer, the skeletal α -actin promoter, the muscle creatine kinase promoter/enhancer and a muscle specific troponin promoter.

In yet another aspect, the non-human transgenic vertebrate animal is selected from the group consisting of rat, mouse, cat, dog, horse, cow, pig, sheep, goat, fish, bird, and human.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a diagram depicting the structure of the IGF-I rAAV construct. Rat IGF-I cDNA was placed under the control of a fast muscle-specific promoter/regulatory sequence (myosin light chain 1/3 termed "MLC 1/3") positioned at the 5' end of the IGF-I cDNA. A SV40 polyadenylation sequence (SV40pA) was positioned at the 3' end of the IGF-I cDNA. On the 3' end of the SV40pA sequence, the MLC 1/3 enhancer sequence was inserted into the construct. The gene construct was then inserted into a rAAV transfer plasmid (pSUB201) between the inverted terminal repeat sequences (ITRs) of the virus.

Figures 1B, 1C, and 1D are images of a gel depicting the persistence of IGF-I expression in muscle following injection therein with rAAV- IGF-I wherein IGF-I expression was detected by reverse-transcriptase polymerase chain reaction (RT-PCR) assay. The lanes were loaded with sample RT-PCR reactions performed on nucleic acid obtained from the following muscle tissues: Lane 1, 27-month-old extensor digitorum longus (EDL) 9 months post-rAAV-IGF-I injection; lane 2, 6-month-old EDL at 4 months post-rAAV-IGF-I injection; lane 3, uninjected age-matched control EDL; lane 4, positive control using the rAAV-IGF-I gene construct depicted in Figure 1A. The expression of IGF-I in the various muscle tissues compared to the positive control in lane 4 is depicted in Figure 1B. The constitutive

expression of β -cytoplasmic actin in EDL is depicted in Figure 1C. In this panel, lanes 1-3 were loaded as described previously. Lane 4 is a positive control using a template supplied with oligonucleotides obtained from Clontech Laboratories, Inc. (Palo Alto, CA). In Figure 1D, data demonstrating the integrity of RNA isolated from EDL muscles which was analyzed as described in the top and middle panels is shown. Equal volume RNA samples were electrophoresed through a non-denaturing agarose gel (Invitrogen, Carlsbad, CA). Lanes 1-3 were loaded as described previously herein.

Figure 2A, comprising Figures 2Ai and 2Aii, is a pair of images of photomicrographs depicting the effect of IGF-I expression in EDL muscles of young (6 month old) mice 4 months post-rAAV-IGF-I injection. Cross-sections of control non-injected and rAAV-IGF-I-injected EDL muscles were stained with hemotoxinil and eosin. rAAV-IGF-I-injected EDL (Figure 2Aii) displayed significant increase in cross-sectional area compared with contralateral non-injected EDL (Figure 2Ai). Muscle fiber regeneration was evident in rAAV-IGF-I-injected EDL as demonstrated by the presence of central nuclei (Figure 2Aii, insert) which were absent in non-injected EDL muscle (Figure 2Ai, insert). Scale bars equal 100 μ m.

Figure 2B is a graph depicting the effect of IGF-I expression on muscle mass and force generation. Muscle mass (wet weight) and isometric tetanic force of rAAV-IGF-I-injected muscles were expressed relative to the same measurements in the contralateral non-injected muscles. The symbol "*" denotes $p < 0.05$ for paired comparisons between rAAV-IGF-I-injected and control muscles.

Figure 3, comprising Figures 3A, 3B, and 3C, is a series of graphs depicting the effect of IGF-I expression in EDL muscles of old (27-month) mice compared to control non-injected young (6-month) mice and old (27-month) mice EDLs. In Figure 3A, the graph depicts (from left to right) the muscle mass (wet weight) of young, control EDL; old, control EDL; and rAAV-IGF-I-injected old EDL, respectively. In Figure 3B, the graph depicts (from left to right) the tetanic force of young control EDL, old control EDL, and rAAV-IGF-I-injected old EDL, respectively. In Figure 3C, the graph depicts (from left to right) the specific force of young control

EDL, old control EDL, and rAAV-IGF-I-injected old EDL, respectively. For determination of specific force, the cross-sectional area of the EDL muscle was estimated using muscle mass and optimum muscle length pursuant to Brooks and Faulkner (1988, J. Physiol. 404:71-82). The symbol "*" denotes p<0.05 for comparisons to young adult control muscles.

Figure 4 is the nucleotide sequence of the rat liver form of IGF-1.

Figure 5, comprising Figures 5A and 5B is a pair of images of the muscles of a transgenic mouse having the MLC/IGF-1 construct (Figure 5B), compared with the muscles of an otherwise identical non-transgenic mouse (Figure 5A).

DETAILED DESCRIPTION OF THE INVENTION

It has been discovered in the present invention that introduction of an isolated nucleic acid encoding IGF-I into adult muscle cells, wherein IGF-I is then expressed in the adult muscle cells, results in hypertrophy of the muscle and/or reversal of age-related muscular atrophy. More importantly, in contrast to prior art procedures, the overall strength of the muscle is enhanced. Without wishing to be bound by theory, it may be that recombinant virus-mediated muscle fiber expression of IGF-I activates satellite cells where prior art methods failed to do so in that prior art procedures did not sufficiently elevate local levels of IGF-I in the muscle. Alternatively, it may be that systemic IGF-I failed to gain access into and to activate satellite cells. In any event, the present invention has circumvented the obstacles which prior art compositions and procedures failed to overcome.

Senescence in mammals is accompanied by loss of strength and endurance in the skeletal musculature. This is due, *inter alia*, to a diminution in the average diameter of muscle fibers, a shift to less powerful muscle fiber types, decreased mitochondrial volume, and decreased mitochondrial efficiency. The most significant loss of muscle mass in adult muscle is due to the reduction in the number and/or size of the largest, most powerful muscle fibers, the type IIb and type IIx fibers.

The invention relates to the introduction of IGF-I into adult muscle. In a preferred embodiment, a recombinant viral vector delivery system, *i.e.*, an adeno-associated viral (AAV) vector, was used to introduce nucleic acid encoding IGF-I into the muscle tissue of a mammal. However, the invention should not be construed to be limited to any particular vector or to any particular strain of AAV. Rather, the invention should be construed to include all other means of introducing nucleic acid encoding IGF-I into muscle cells including, but not limited to, any strain of AAV which is capable of delivering genes to muscles cells (for example, including, but not limited to, AAV-1, AAV-3, AAV-4 and AAV-6), other viruses including adenoviruses, herpes simplex viruses, retroviruses, and the like. The invention also includes plasmid-based delivery vectors as well as the administration of DNA in the absence of any vector such as administration of naked DNA by a "gene gun" approach, or the administration of coated DNA, or any other method facilitating DNA entry into muscle tissue.

By the term "naked DNA" as used herein, is meant DNA, which, irrespective of the route or method of administration, is administered to an animal in the absence of any substantial amount of protein, lipid, or any other compound either covalently bound to or non-covalently associated with the DNA. For example, naked DNA includes but is not limited to a plasmid or an isolated nucleic acid fragment encoding a sequence of interest whether naturally or synthetically derived.

An "isolated nucleic acid," as the term is used herein, refers to a nucleic acid sequence, segment, or fragment which has been separated from the sequences which flank it in a naturally occurring state, *e.g.*, a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, *e.g.*, the sequences adjacent to the fragment in a genome in which it naturally occurs. The term also applies to nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, *e.g.*, RNA or DNA or proteins, in the cell. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus;

or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (*e.g.*, as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

As used herein, the term "substantially purified" describes a compound, *e.g.*, a protein or polypeptide which has been separated from components which naturally accompany it. Typically, a compound is substantially pure when at least 10%, more preferably at least 20%, more preferably at least 50%, more preferably at least 60%, more preferably at least 75%, more preferably at least 90%, and most preferably at least 99% of the total material (by volume, by wet or dry weight, or by mole percent or mole fraction) in a sample is the compound of interest. Purity can be measured by any appropriate method, *e.g.*, in the case of polypeptides by column chromatography, gel electrophoresis or HPLC analysis. A compound, *e.g.*, a protein, is also substantially purified when it is essentially free of naturally associated components or when it is separated from the native contaminants which accompany it in its natural state.

The term "coated DNA," as used herein, describes a DNA associated with a non-proteinaceous substance which may be administered to an animal. Such non-proteinaceous substances include but are not limited to lipids, polylysine, glycosylated polylysine, and the like.

In a preferred embodiment, the IGF-I coding sequence used in the compositions and methods of the invention is the 0.6 kb rat IGF-I cDNA. The invention, however, is not limited solely to this IGF-I DNA. Instead, the invention encompasses any and all IGF-I coding sequences having the biological activity of IGF-I including promoting muscular hypertrophy and enhancing muscle strength as described herein. For example, the invention should be construed to include all mammalian IGF-I sequences which are either known or unknown. The preferred type of IGF-I to be used depends upon the species of animal being treated, in that, the it is

preferred that the IGF-1 be species matched. Thus, for example, when a human is being treated, the preferred type of IGF-1 is human IGF-1, etc. Although all forms of IGF-1 are likely to have an effect in different animals, species matching will void potential adverse immunological complications stemming from the induction of an immune response to an IGF-1 of a different species in any given animal. Sources of IGF-1 from different animal species include the following types of IGF-1 and accompanying GenBank Accession Numbers: Cervus elaphus insulin-like growth factor I (IGF-I) mRNA, Accession No. U62106; Equus caballus insulin-like growth factor I precursor (IGF-I) mRNA, Accession No. U28070; Goat mRNA for insulin-like growth factor-I, Accession No. D11378; Oryctolagus cuniculus insulin-like growth factor 1 precursor (IGF-1) mRNA, Accession No. U75390; Pig insulin-like growth factor I (pIGF-I) mRNA, Accession No. M31175; Ovis aries insulin-like growth factor I (IGF-I) mRNA, Accession No. M89787; Human insulin-like growth factor (IGF-I) IA and IB gene, exon 1, Accession Nos. M12659, M77496; Rat insulin-like growth factor I (IGF-I) mRNA, Accession No. M15480; Chicken insulin-like growth factor (IGF-I) mRNA, Accession Nos. M32791, M29720; Salmon insulin-like growth factor I (IGF-I) mRNA, M32792; X. laevis insulin-like growth factor I (IGF-I) mRNA, Accession No. M29857. Thus, the invention should be construed to include DNA encoding IGF-I, or a biologically active portion thereof, from humans and non-human mammals, including but not limited to mouse, human, cow, pig, horse, sheep, rat, goat, Xenopus, and the like, which IGF-I functions in a substantially similar manner to the rat IGF-I described herein. Furthermore, IGF-1 is thought to serve a similar role in other vertebrates as it does in mammals. Thus, transgenic fish or birds having and expressing IGF-1 in mature muscle fibers (i.e., via the use of muscle specific promoters) will result in increased muscle mass in juvenile and adult animals. In preliminary experiments using bird muscle cells in vitro, it is evident that IGF-1 has an effect on these cells, which effect is predictive that treatment of avian, fish and other muscle cells with the appropriate IGF-1 will serve to increase the mass and strength of muscle tissue in these animals.

The term "non-human transgenic vertebrate animal" as used herein means an animal, the somatic and germ cells of which comprise an isolated nucleic acid comprising IGF-1.

Preferably, the nucleotide sequence comprising the gene encoding IGF-I is about 50% homologous, more preferably about 70% homologous, even more preferably about 80% homologous and most preferably about 90% homologous to the gene encoding human IGF-I and whose sequence is provided in (1986, J. Biol. Chem. 261:4828-4832). It should be noted that alternative RNA processing in the cell results in the production of two IGF-1 precursor polypeptides and that both forms work in the experiments described herein. In addition, IGF-1 obtained from rat liver or muscle may be used for comparison (1987, Mol. Endocrinol. 1:243-248).

The use of the term "DNA encoding" should be construed to include the DNA sequence which encodes the desired protein and any necessary 5' or 3' untranslated regions accompanying the actual coding sequence.

The term "expression of a nucleic acid" as used herein means the synthesis of the protein product encoded by the nucleic acid.

By "biologically active" as used herein, is meant an IGF-I protein, or any portion, modification or variant thereof, which is capable of mediating a substantially similar increase in and/or prevention of the loss of muscle mass and specific muscle strength as demonstrated for rat IGF-I as measured by the methods described herein.

By the term "specific strength," as used herein, is meant the force generated by a muscle divided by its cross-sectional area as determined pursuant to the methods described by Brooks and Faulkner (1988, J. Physiol. 404:71-82).

The invention should also be construed to include DNA encoding variants of IGF-I which retain IGF-I biological activity as defined previously herein. Such variants, *i.e.*, analogs of proteins or polypeptides of IGF-I, include proteins or polypeptides which have been or may be modified using recombinant DNA technology such that the protein or polypeptide possesses additional properties which enhance its

suitability for use in the methods described herein, for example, but not limited to, variants conferring enhanced stability on the protein in muscle, enhanced specific activity of the protein, and increased ability of the protein to remain localized in muscle tissues. Analogs can differ from naturally occurring proteins or peptides by
5 conservative amino acid sequence differences or by modifications which do not affect sequence, or by both. For example, conservative amino acid changes may be made, which although they alter the primary sequence of the protein or peptide, do not normally alter its function. Conservative amino acid substitutions typically include substitutions within the following groups:

- 10 glycine, alanine;
 valine, isoleucine, leucine;
 aspartic acid, glutamic acid;
 asparagine, glutamine;
 serine, threonine;
15 lysine, arginine;
 phenylalanine, tyrosine.

Preferably, the amino acid sequence of an IGF-I analog is about 70% homologous, more preferably about 80% homologous, even more preferably about 90% homologous, more preferably, about 95% homologous, and most preferably, at least about 99% homologous to the amino acid sequence of IGF-I described in (1986, J. Biol. Chem. 261:4828-4832) and in (1987, Mol. Endocrinol. 1:243-248).

"Homologous" as used herein, refers to the subunit sequence similarity between two polymeric molecules, *e.g.*, between two nucleic acid molecules, *e.g.*, two DNA molecules or two RNA molecules, or between two polypeptide molecules. When 25 a subunit position in both of the two molecules is occupied by the same monomeric subunit, *e.g.*, if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions, *e.g.*, if half (*e.g.*, five positions in a polymer ten subunits in length) of the positions in two compound

sequences are homologous then the two sequences are 50% homologous, if 90% of the positions, e.g., 9 of 10, are matched or homologous, the two sequences share 90% homology. By way of example, the DNA sequences 3' ATTGCC 5' and 3' TATGCG 5' share 50% homology.

5 Any number of procedures may be used for the generation of mutant or variant forms of IGF-I. For example, generation of mutant forms of IGF-I which do not circulate in the plasma of rAAV-IGF-I-injected animals may be accomplished by introducing deletion, substitution or insertion mutations into an IGF-I encoding nucleic acid residing on a plasmid template using ordinary recombinant DNA methodology
10 described in any molecular biology manual, for example, methods described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York) and Ausubel et al. (1997, Current Protocols in Molecular Biology, Green & Wiley, New York). Mutant IGF-I so generated is expressed and the resulting protein is assessed for its ability to remain localized in the muscle as
15 demonstrated by a lack of significant increase in plasma levels of IGF-I such as that described herein. Mutant proteins which appear to be localized to the muscle tissues are then tested for IGF-I biological activity as defined herein. DNA encoding a mutated IGF-I protein which does not cause a significant rise in IGF-I plasma levels but which retains IGF-I biological activity, is suitable for use in the rAAV vector of the
20 invention.

Procedures for the introduction of amino acid changes in a protein or polypeptide by altering the DNA sequence encoding the polypeptide are well known in the art and are also described in Sambrook *et al.*, *supra*, and Ausubel *et al.*, *supra*.

It is desirable but not essential that the nucleic acid encoding IGF-I
25 which is introduced into muscle cells in a mammal be expressed and that the protein remain localized within the muscle tissue. This is because if higher than physiologically normal amounts of IGF-I enter the circulatory system, IGF-I may promote undesired growth of other cells which may result in detrimental rather than beneficial effects to the mammal into which IGF-I has been introduced. Thus, the

present invention also relates to the use of a truncated form of IGF-I which prevents egress of IGF-I from the muscle tissue into the circulatory system. Such a truncated form is described, for example, in Sara et al. (1986, *Physiol. Rev.* 70:591-614), wherein there is disclosed a truncated form of IGF-1 which is missing the three terminal amino acids in the mature IGF-1 peptide.

Accordingly, in a preferred embodiment, the nucleic acid encoding IGF-I introduced into the muscle cells encodes a truncated version of IGF-I which is expressed therefrom. The truncated version of the full-length rat IGF-I cDNA disclosed herein is preferably missing the three terminal amino acids in the mature IGF-1 peptide. Expression in muscle of the truncated version does not cause measurable increase in plasma levels of IGF-I in mice as detected by standard methods as set forth herein.

In a preferred embodiment, the invention relates to the use of a muscle specific promoter/regulatory region, *i.e.*, the MLC 1/3 promoter, such that DNA encoding IGF-I operably linked to the promoter/regulatory region is expressed at highest levels in type IIb/x fibers. However, the invention is not limited to the use of this or any other particular promoter/regulatory region to drive expression of the DNA encoding IGF-I. Indeed, other promoter/regulatory regions capable of driving expression of a heterologous gene to high levels in muscle cells, more desirably, in type IIb/x muscle cells, include, but are not limited to, the skeletal α -actin promoter and the muscle creatine kinase promoter/enhancer, and the like. Other muscle specific promoters may be used, including the skeletal muscle troponin subunit promoter, such as the fast troponin C promoter/enhancer sequence. It is important to note that it is preferable to use a muscle specific promoter when administering IGF-1 to an animal, although it is possible to use a variety of non-muscle specific promoters as well, including constitutive promoters such as viral promoters. However, when the invention includes expression of IGF-1 in a transgenic animal, a muscle specific promoter is the promoter of choice, in order to avoid any potential deleterious side effects which may arise as a result of expression of IGF-1 in non-muscle tissue.

In another preferred embodiment, the rAAV-IGF-I recombinant of the invention comprises several DNA elements. These DNA elements include at least two copies of an AAV inverted terminal repeat (ITR) sequence, a 1.5 kb MLC 1/3 promoter/regulatory element previously discussed herein, a 0.85 kb SV40 polyadenylation sequence signal, and a 0.9 kb MLC 1/3 enhancer element, all operably linked to the IGF-I DNA coding region, as well as any necessary 5' or 3' untranslated regions which flank the DNA encoding IGF-I. However, the invention should not be interpreted as being limited to the presence of any or all of these particular elements or to any particular arrangement thereof. Rather, the invention encompasses other 5 promoter/regulatory regions, enhancers, polyadenylation signal sequences, and the like, arranged in various orders and permutations thereof. Further, the invention includes constructs which do not have one or more of the above-stated DNA elements.

10 promoter/regulatory regions, enhancers, polyadenylation signal sequences, and the like, arranged in various orders and permutations thereof. Further, the invention includes constructs which do not have one or more of the above-stated DNA elements.

As used herein, the term "promoter/regulatory sequence" means a DNA sequence which is required for expression of a gene operably linked to the 15 promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene in an inducible/repressible or tissue-specific manner.

By describing two nucleic acids as being "operably linked" as used 20 herein, is meant that a single-stranded or double-stranded nucleic acid comprises each of the two nucleic acids and that the two nucleic acids are arranged within the nucleic acid in such a manner that at least one of the nucleic acid sequences is able to exert a physiological effect by which it is characterized upon the other.

By the term "positioned at the 5' end" as used herein, is meant that the 25 promoter/regulatory sequence is covalently bound to the 5' end of the gene whose expression it regulates, at a position sufficiently close to the 5' start site of transcription of the gene so as to drive expression of the gene.

The rAAV vector of the invention also comprises 5' and 3' untranslated regions of DNA which flank the 0.6 kb rat IGF-I cDNA sequence. In the rAAV-IGF-I

vector exemplified in the experimental examples section, the 5' untranslated region flanking the IGF-I sequences is as follows: At the 5' end of the IGF-I sequences, the 1.5 kb MLC 1/3 promoter sequence.

A first region of an oligonucleotide "flanks" a second region of the oligonucleotide if the two regions are adjacent one another or if the two regions are separated by no more than about 1000 nucleotide residues, and preferably no more than about 100 nucleotide residues.

In the rAAV-IGF-I vector exemplified in the experimental details section, the 3' untranslated region flanking the IGF-I sequences is as follows: At the end of the translation stop signal, is the 0.85 kb SV40 poly A signal sequence which is followed by the 0.9 kb MLC 1/3 enhancer sequence.

It will be appreciated that other 5' and 3' untranslated regions of DNA may be used in place of those recited in the case of IGF-I.

The rAAV vector of the invention also comprises a transcription termination signal. While any transcription termination signal may be included in the vector of the invention, preferably, the transcription termination signal is the SV40 transcription termination signal.

In a preferred embodiment, a muscle enhancing dose of about 10^{10} plaque-forming units (pfu) of rAAV-IGF-I recombinant was administered to the muscle tissue of mice.

By the term "muscle enhancing dose" as the term is used herein, is meant a dose of an isolated nucleic acid, preferably but not necessarily in a recombinant virus vector, wherein the isolated nucleic acid encodes a mammalian IGF-I gene, wherein the isolated nucleic acid is administered to a muscle and IGF-I expressed therefrom induces an increase in muscle size and muscle strength compared with muscle to which an isolated nucleic acid is not administered or with a muscle to which a similar isolated nucleic acid dose is administered which either does not encode or does not express IGF-I.

By the term "administered" as used herein, is meant any method for the introduction of an isolated nucleic acid into muscle tissue. One preferred method is injection of the nucleic acid, or a recombinant vector comprising the nucleic acid either directly into the muscle or into the interstitial space surrounding the muscle of a vertebrate animal. Alternatively, systemic delivery of viral vectors or any other means by which isolated nucleic acid can be introduced into muscle cells including "gene gun", liposomes, and the like are also included in the invention.

The invention is not limited solely to the delivery of factors for the treatment of aging-associated loss of muscle mass and function. Rather, the invention should be construed to include a variety of vectors encoding other muscle enhancing factors for the treatment of various muscle disorders or conditions, which factors may be delivered using the methods of the present invention to the muscle cells of a mammal. Thus, the invention should be construed to include delivery of fibroblast growth factor, neurotrophins, and the like, in combination with IGF-1, or delivery of IGF-1 alone to vertebrates.

The invention should also be construed to include nucleic acids encoding various proteins which are useful for the treatment of other muscle associated disease states in a mammal. Such muscle associated disease states include, but are not limited to, Becker muscular dystrophy, Duchenne muscular dystrophy, Limb Girdle muscular dystrophy, facioscapulohumeral dystrophy, spinal muscular dystrophy and amyotrophic lateral sclerosis.

By "therapeutic effect" as used herein as it relates to IGF-I, is meant any increase in muscle mass and muscle strength and/or prevention of loss of muscle mass and muscle strength caused by senescence, disease, weightlessness, or any other condition which causes decrease in muscle mass or strength.

According to the invention, it has been discovered that a preparation of an rAAV vector comprising nucleic acid encoding IGF-I injected into the muscle tissue of an animal at a single site per dose increases muscle mass and strength in young animals and prevents loss of muscle mass and strength in old animals. However, the

invention is not limited to this injection regimen. Rather, treatment regimens which are contemplated include a single dose or dosage which is administered hourly, daily, weekly or monthly, or yearly.

5 The route of administration of the vaccine may also vary depending upon the disorder to be treated.

Typically, the number of viral vector genomes per gram of muscle which are administered in a single injection ranges from about 10^9 to about 10^{13} . More preferably, the number of viral vector genomes/mammal which are administered in a single injection is about 2×10^{10} viral genomes per gram of muscle.

10 When the method of the invention comprises multiple site simultaneous injections, or several multiple site injections comprising injections into different muscle sites over a period of several hours (for example, from about less than one hour to about two or three hours), the total number of viral vector genomes administered is identical to that recited in the single site injection method.

15 For administration of the rAAV vector of the invention in a single site injection, a suspension of virus is injected directly into the muscle. For multiple site injection, a needle is inserted into the muscle tissue of the mammal. The vector is injected essentially continuously along the needle track so that a series of intramuscular sites are injected with each injection, each site therefore being at a position further into the muscle tissue than the previous site. Each injection targets from about 5 to about 30 sites along the needle track and patients may receive about 50 total injections. The procedure is therefore akin to an acupuncture procedure which is preferably carried out under anesthesia.

20 Multiple site injection of rAAV may also be accomplished using a multiple injection device such as that commonly used for the detection of tuberculosis infection.

25 In a preferred embodiment, the rAAV-IGF-I vector is suspended in a solution of 10% glycerol/HBS. However, the invention is not limited to this formulation. Rather, for administration to the mammal, the rAAV vector comprising

IGF-I may be suspended in any pharmaceutically acceptable carrier, for example, HEPES buffered saline at a pH of about 7.8. Other pharmaceutically acceptable carriers which are useful include, but are not limited to, glycerol, water, saline, ethanol and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).

The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides.

The rAAV vector of the invention may also be provided in the form of a kit, the kit comprising, for example, a freeze-dried preparation of vector in a dried salts formulation, sterile water for suspension of the vector/salts composition and instructions for suspension of the vector and administration of the same to the mammal.

Thus, included in the invention is a kit for enhancing or preventing the loss of muscle mass and strength. The kit comprises a muscle enhancing dose of an isolated nucleic acid encoding an IGF-I, or a biologically active portion thereof, and/or a recombinant vector comprising the nucleic acid, and an applicator for administering the nucleic acid to muscles, and instructions for using the kit. The instructions for using the kit depend on the particular human or veterinary patient for which the kit is to be used and the target muscle site(s).

In a preferred embodiment, the instructions comprise directions on how to administer a rAAV-IGF-I recombinant to the hind limb of mice. These instructions simply embody the examples provided herein.

The kit may also include instructions on how to administer the rAAV-
5 IGF-I recombinant using the applicator provided therewith.

By the term "applicator" as the term is used herein, is meant any device including but not limited to a hypodermic syringe, a gene gun, and the like, for administering the DNA encoding IGF-I, or a biologically active portion thereof, into the muscles of a human or veterinary patient.

10 The compositions and methods described herein have the following applications. Muscle strength in aging humans may be preserved and/or enhanced; injured muscle may be caused to heal more effectively and more rapidly; muscle mass may be controlled during disease and/or during prolonged stays in reduced gravity environments; cosmetic body sculpting may be possible by promoting muscle
15 hypertrophy in selected muscle tissue; muscle growth in young animals may be enhanced; muscle mass in adult animals may be enhanced; and, in diabetes, the compositions and methods may be useful for the promotion of glucose clearance from the muscle tissue.

IGF-1 is also known to promote glucose uptake in skeletal muscle in an
20 insulin-independent manner, and thus, also be of use in controlling blood glucose levels in diabetics.

In addition as noted herein, the invention includes a non-human transgenic vertebrate animal comprising an isolated nucleic acid comprising IGF-1, which IGF-1 is preferably operably linked to a muscle specific promoter/regulatory
25 region at its 5' end, and also comprises a polyadenylation signal at its 3' end. Such non-human transgenic vertebrate animals are expected to comprise up to or even more than 50% more muscle mass than their otherwise identical non-transgenic counterparts. In addition, the muscle mass of the transgenic animal progresses much faster than that of an otherwise identical non-transgenic counterpart animal. Thus, when used as a source

of food, the transgenic animal of the invention may be brought to market faster than the non-transgenic counterpart animal. The generation of transgenic animals is well known in the art and is described, for example, in Hogan et al. (1986, Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor, New York).

5 The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a
10 result of the teaching provided herein.

Example 1: Expression of exogenous IGF-I in muscle induces hypertrophy and increased muscle strength in young animals and prevents loss of muscle mass and function in older animals

15 The experiments presented in this example may be summarized as follows.

The data presented herein demonstrate that exogenous production of IGF-I in mammalian muscle increases both muscle mass and muscle strength in young animals and prevents the loss of muscle mass and muscle function in older animals. More specifically, a recombinant adeno-associated virus (rAAV) vector expressing
20 high levels of IGF-I under the control of the MLC 1/3 promoter/enhancer sequence was injected into the right hindlimb muscle of either young (*i.e.*, 2 months of age) or old (*i.e.*, 18 or 24 months of age) mice. The muscle was examined to determine its mass and function at 4 or 9 months after viral injection. In young mice examined at 6 months of age after viral administration at 2 months, the muscle exhibited a 15%
25 increase in mass with a concomitant increase of 14% in isometric force.

The results obtained in old mice where muscles were injected with rAAV-IGF-I were even more remarkable than those observed in young mice. In old mice, the data obtained therefrom demonstrated an increase in muscle mass of 19%

compared with the control, non-injected muscle; therefore, the normal 15% decrease in muscle mass normally associated with aging in mice was completely prevented.

Functionally, the rAAV-IGF-I-injected muscle of old mice exhibited increased force relative to control contralateral muscles which was even greater than the increase in cross sectional area thereby completely preventing the loss of specific force (defined as force per cross-sectional area) typically seen in aging skeletal muscle in mice. Further, the rAAV-IGF-I-injected muscle demonstrated specific preservation of the most powerful and fastest muscle fibers, type IIb fibers, normally lost in aging muscle. The selective preservation of type IIb fibers may explain the preservation of specific force observed in rAAV-IGF-I-injected muscle of old mice compared with control muscle of old mice which generated less force per cross-sectional area when compared to the muscles of young mice.

It has therefore been discovered that injection of a rAAV expressing high levels of IGF-I in differentiated muscle fibers, promotes an average increase of 15% in muscle mass and a 14% increase in muscle strength in young adult mice. Even more remarkably, rAAV-IGF-I injection prevents aging-related muscle changes in old adult mice, resulting in a 19% increase in muscle mass and a 27% increase in specific strength compared with uninjected muscles in old mice. Further, rAAV-IGF-I-injected muscles of old mice demonstrated that muscle mass and fiber types were maintained at levels similar to those observed in control, young adult muscles.

Without wishing to be bound by theory, it may be that these effects observed in muscles injected with rAAV-IGF-I recombinant virus are primarily due to stimulation of muscle regeneration by IGF-I which is expressed locally within the muscle, and that the primary cause of aging-related impairment of muscle function is a cumulative failure to repair damage sustained during muscle utilization which repair is somehow mediated by IGF-I. The results disclosed herein suggest that gene transfer of IGF-I into muscle may be an effective human gene therapy for preventing the loss of muscle function associated with aging, and may be of benefit in diseases or conditions where there is loss of muscle mass and/or muscle strength. Such conditions or diseases

include, but are not limited to, loss of muscle strength in aging humans; treatment of injured muscle; muscle atrophy caused by disease and/or reduced gravity environments; cosmetic body sculpting including repair of damaged muscle following injury; inducing muscle growth in young animals; increasing muscle mass and strength in adult animals; and promotion of glucose clearance from the muscle tissue in diabetics. In addition, the viral delivery of IGF-1 may have therapeutic value in the several diseases, including, but not necessarily limited to, Becker muscular dystrophy, Duchenne muscular dystrophy, Limb Girdle muscular dystrophy, facioscapulohumeral dystrophy, spinal muscular dystrophy and amyotrophic lateral sclerosis.

10 The Materials and Methods used in the experiments presented in this example are now described.

Viral Construct

Figure 1A depicts a schematic diagram of the IGF-I construct. An AAV transfer plasmid (pSUB201) was constructed which contained a myosin light chain (MLC) 1/3 promoter/regulatory sequence, which is known to drive expression of target genes operably linked to the sequence, in differentiated fast-twitch muscle fibers (Allen *et al.*, 1989, *J. Cell Physiol.*, 138:311-314). Rat IGF-I cDNA (Shimatsu *et al.*, 1987, *J. Biol. Chem.* 262:7894-7900) was inserted into pSUB201 and was operably linked to the MLC 1/3 promoter/regulatory sequence. This promoter/regulatory sequence comprises a 1500 bp MLC1 promoter fragment placed upstream and a 920 bp MLC enhancer fragment placed downstream of the IGF-I transcription cassette. The MLC promoter/regulatory regions were chosen because they have been reported to activate transgene expression in the correct developmental time frame (E9.5) in the mouse and to drive transgene expression to consistently high levels exclusively in adult skeletal muscle (Donoghue *et al.*, 1988, *Genes and Development* 2:1779-1790; Rosenthal *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:7780-7784; Rosenthal *et al.*, 1990, *Nucl. Acids Res.* 18:6239-6245; Benecke *et al.*, 1992, *Diabetes* 42:206-212).

The coding sequence of a rat liver form of IGF-1, as disclosed by Shimatsu *et al.* (1987, *J. Biol. Chem.* 262:7894-7900) was ligated to a SV40-derived

intron and a SV40 polyadenylation site was placed downstream of the coding sequences for optimal RNA processing and stability. The DNA sequence is SEQ ID NO:3 as shown in Figure 4.

The IGF-I cDNA sequences were placed under the control of a dual promoter/enhancer combination sequence derived from the rat MLC 1/3 locus. The entire cassette was then cloned into the AAV vector genome between the AAV ITRs (Figure 1A) and a recombinant AAV was prepared by the University of North Carolina Gene Therapy Vector Core (Chapel Hill, NC), following published procedures (Snider *et al.*, 1996, In: Current Protocols in Human Genetics pp. 12.1.1-12.1.24, John Wiley and Sons Press, New York; Juan Li *et al.*, 1996, J. Virol. 70:8098-8108; Samulski *et al.*, 1989, J. Virol. 63:3822-3828).

Injections

Anesthetized C57BL/6 mice of 2, 18, and 24 months of age were injected with 50 µl of 10% glycerol/HBS containing approximately 10^{10} rAAV particles (Donoghue *et al.*, 1988, Genes & Development 2:1779-1790) into the interstitial space surrounding the anterior muscles of the right hind limb, which included the extensor digitorum longus (EDL). Briefly, the virus was administered to the mice by injection into the area beneath the connective tissue sheath overlying the targeted muscle using a glass micropipette and a pressure delivery device, or by using a 30 gauge needle. Once the mice regained consciousness, they were returned to the animal facility until further study.

Mechanical Measurements

Approximately 4 or 9 months after viral injection, the mice were sacrificed by cervical dislocation under anesthesia, and the EDL muscles were removed to determine isolated muscle force measurements. The tendons were attached to a rigid post and to an isometric force transducer in a bath of Ringers solution which was gas-equilibrated with 95% O₂/5% CO₂. The optimum length of the muscle was determined by twitch force from supramaximal stimulation. Maximal tetanic force was determined using a 120 Hz -- 500 msec pulse which was delivered via two parallel

platinum plate electrodes. After the force measurements were completed, the muscles were removed from the bath, blotted to remove excess moisture, and weighed. The muscles were then pinned at optimum length, surrounded by embedding compound (TissueTek), and rapidly frozen in melting isopentane. Muscles were stored at -80°C until subsequent analysis.

5

Histology

All muscle tissues were prepared and stained with hematoxylin and eosin as described by Carson (1997, In: Histotechnology, American Society of Clinical Pathologists, Chicago).

10 Detection of Transgene Expression

RT-PCR was performed to detect the presence of IGF-I transcripts in injected muscles. The recombinant DNA methods used are well-known in the art and have been described previously (Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York; Ausubel *et al.*, 15 1997, Current Protocols in Molecular Biology, Green & Wiley, New York). Briefly, total RNA isolated from frozen tissue (RNAqueous, Ambion, Austin, TX) was subject to reverse transcription and PCR (Perkin Elmer, CA) using oligonucleotides specific for rat IGF-I (TGCTCACCTTACCAGCTCGG [SEQ ID NO: 1], sense primer; GCCCGGATGGAACGAGCTGACT [SEQ. ID NO: 2], antisense primer). The 20 primers which amplified β cytoplasmic actin (Clontech, CA) served as a positive control for the procedure.

20

Myosin Heavy Chain Composition

Immunohistochemistry was performed to determine neonatal and type IIb myosin heavy chain composition in EDL muscles (Schiaffino *et al.*, 1997, In: 25 Methods in Cell Biology, pp. 349-367, Emerson and Sweeney, eds., Academic Press, New York). Primary antibody dilutions used were as follows: Type I myosin (BA-F8), 1:50; Type IIa myosin (SC-71), 1:10; Type IIb myosin (BF-F3), 1:3; Neonatal myosin (BF-34), 1:10. AMCA-conjugated, goat anti-mouse IgM antibodies and donkey anti-mouse IgG (H+L) (Jackson ImmunoResearch Laboratories, Inc. (West

grove, PA)) were used as secondary antibodies. Microscopy was performed using a Leitz DMR microscope (Leica, Inc. Exton, PA). Image acquisition and analysis was carried out using a MicroMAX digital camera system (Princeton Instruments, Trenton, NJ) and imaging software (IPLAB, Signal Analytics, Vienna, VA).

5 The Results of the experiments presented in this example are now described.

Injection of rAAV expressing IGF-I into muscles of young mice induces increase in both muscle mass and muscle strength and prevents loss of muscle mass and force in old mice

10 Figure 1B illustrates expression of the viral driven IGF-I mRNA resulting from direct muscle injection of the rAAV-IGF-I construct the structure of which is shown schematically in Figure 1A. The IGF-I expression persisted for as long a period as was examined; for mice examined at 27 months of age, following rAAV-IGF-I injection at 18 months of age, this represents 9 months of continued expression.

15 The effects of this IGF-I expression on muscle morphology are demonstrated in Figure 2A in hematoxylin and eosin stained muscle cross sections. In young adult mice (examined at 6 months of age following rAAV-IGF-I injection at 2 months of age), the average mass of the extensor digitorum longus (EDL) muscle increased by 15%. Further, central nuclei were visible in the muscle fibers which is indicative of ongoing regeneration (Carlson *et al.*, 1983, Med. Sci. Sports Exerc. 15:187-198). Additionally, the presence of neonatal myosin in rAAV-IGF-I-injected muscles provides further evidence of regeneration since developmental expression of myosin has also been demonstrated to accompany regeneration. Indeed, Sartore *et al.* (1982, Nature 298:294-296), demonstrated that when satellite cells are activated and fuse with existing muscle fibers, their nuclei recapitulate the progression through the series of developmental myosin heavy chain isoforms. Thus, expression of developmental myosin heavy chain isoforms further confirms satellite cell activation and muscle regeneration in rAAV-IGF-I-injected muscles.

In the case of the old mice examined at 27 months of age following rAAV-IGF-I injection at either 18 or 24 months of age, the muscle mass increased 19% compared with control non-injected muscle. Thus, the normal decrease of muscle mass associated with aging (15% in mice) was completely prevented by viral administration of IGF-I (Figure 3). Moreover, similar to the situation observed in the young animals, central nuclei were evident in muscle cells at 4 months following viral injection in the old animals. However, at 9 months following injection, no central nuclei were observed even though IGF-I expression was maintained (Figure 1B). This suggests that the muscles eventually reach a new steady state in which regeneration is no longer evident.

From a functional standpoint, the effects of the viral IGF-I expression were even more surprising in extent. In the young animals injected with rAAV-IGF-I, the increase in overall muscle mass and in the muscle cross-sectional area translates into increased force production (isometric force increased by 15%), without any changes in muscle fiber number (control 726 ± 54 ; +rAAV-IGF-I: 785 ± 96), fiber types, or any other contractile parameters. Therefore, these data disclose that hypertrophy of individual fibers has been induced with concomitant increase in force, a result never achieved before in the prior art.

In the old animals, the functional results of IGF-I expression mediated by rAAV-IGF-I injection were even more remarkable. rAAV-IGF-I-injected old mouse muscles demonstrated increased force that was greater than the increase observed in the muscle cross-sectional area (27% increase in force vs. 15% increase in cross-sectional area). Thus, a hallmark of aging skeletal muscle, *i.e.*, reduction in the specific force of muscle (which is defined as the force per cross-sectional area), has been prevented by rAAV-IGF-I injection (Figure 3).

Furthermore, the uninjected, control old EDL muscles exhibited a significant selective loss of the fastest, most powerful fiber types, the IIb fibers (a 24% decrease), which is another hallmark of aging skeletal muscle. However, another remarkable feature of rAAV-IGF-I injection is that it completely prevented this

selective fiber type loss. More specifically, the muscle fiber type make-up of uninjected young animals (64% IIb) and in rAAV-IGF-I-injected young animals (65% IIb) was similar to that in rAAV-IGF-I-injected old animals (69% IIb) which are all much higher than the 45% IIb demonstrated in uninjected old animals. Therefore,
5 rAAV-IGF-I injection prevents the selective loss of the powerful type IIb muscle fibers in old animals.

The effects of the IGF-I production were local. That is, average circulating IGF-I levels were not elevated (248 ± 19.5 ng/ml plasma for control; 217 ± 46.5 ng/ml plasma for rAAV-IGF-I-injected), and the muscles of contralateral
10 limbs of animals receiving single limb injections were indistinguishable from muscles of uninjected animals. This is important because elevation of IGF-I levels in the blood could lead to undesirable deleterious effects in other tissues (Stewart *et al.*, 1996, Physiol. Reviews 76:1005-1026). The mechanism by which IGF-I is restricted to the injected muscle is unclear. Without wishing to be bound by theory, it may be that the
15 muscle extracellular matrix traps secreted IGF-I, or that IGF-I is incapable of gaining access to the blood if secreted from muscle. On the other hand, past failures of increased circulating levels of IGF-I to markedly improve muscle function despite increasing muscle mass (Papadakis *et al.*, 1996, Ann. Intern. Med. 124:708-716), may have resulted either from an inability to sufficiently elevate local concentrations of
20 IGF-I in muscle or from a failure of the circulating IGF-I to gain access into and to activate satellite cells.

The present invention suggests that the mechanism by which the viral-mediated muscle fiber secretion of IGF-I prevents aging-related loss of function is, at least in part (beyond its general anabolic effects), through the activation of satellite
25 cells which leads to increased muscle regeneration. During muscle regeneration, IGF-I levels have been shown to increase (Krishan *et al.*, 1996, J. Muscle Res. and Cell Motility 17:513-521). Additionally, it is known that addition of IGF-I activates satellite cells in culture, increasing the rate of cellular proliferation and formation of myotubes, ultimately resulting in hypertrophied myotubes (Allen *et al.*, 1989, J. Cell

Physiol. 138:311-314). In mice in which satellite cells have been destroyed by irradiation, muscles fail to hypertrophy in response to chronic overload, suggesting that activation of satellite cells is essential for normal hypertrophy (Rosenblatt *et al.*, 1992, J. Appl. Physiol. 73:253-257). That IGF-I-induced satellite cell activation in the experiments described herein is supported by the appearance of central nuclei and developmental myosin heavy chain expression 4 months post-injection of virus. Furthermore, the DNA content of the muscles (Labarca *et al.*, 1980, Anal. Biochem. 102:344-352) increased in excess of the increase in muscle mass (28% increase in DNA content vs. 15% increase in mass). The outcome is preservation of both muscle strength and mass, and prevention of loss of the fastest fiber types (IIb). Based on these results, and without wishing to be bound by theory, it may be that the primary cause of the aging-related loss in strength that precedes, and is in excess of, the loss of muscle mass, is a failure to activate satellite cells in order to repair cumulative injury that results from normal muscle utilization.

15 Example 2: Generation of transgenic animals comprising and expressing an IGF-1 isolated nucleic acid

Transgenic mice were generated which comprise the same MLC-IGF expression cassette as that included in the AAV-IGF construct described herein (excluding the viral ITRs). These mice were generated to test the hypothesis that enhanced IGF-1 expression would induce skeletal muscle hypertrophy and result in an increase in muscle mass in juvenile and adult animals. The generation of such animals has obvious applications for meat producing vertebrates, including fish, birds, cows, sheep, pigs, etc. Previous work has demonstrated that the MLC regulatory elements included in the transgene results in gene expression as early as E9.5 in mouse embryogenesis, and remain highly active in fast fibers, with the highest expression in type IIb fibers.

25 Three established lines of mice having the MLC-IGF transgene were found to express high levels of transgenic IGF-I in fast skeletal muscle. These animals exhibited normal muscle morphology at birth, but by 5 weeks after birth they displayed

marked skeletal muscle hypertrophy compared to non-transgenic mice. Histological analysis of transgenic muscle revealed that fast fibers were approximately 50% larger in cross section than those obtained from wild type animals. This change in relative fast fiber size was also accompanied by an overall shift in fiber composition towards a faster fiber type. Immunocytochemical analysis revealed a predominance of fast Type IIb fibers in the transgenic as compared with wild type muscle, indicating either that Type IIb fibers were preferentially favored early during fiber type diversification or that other fiber types had been transformed into Type IIb by forced IGF-I expression.

In addition, primary myoblasts isolated from transgenic 2 week old animals displayed a precocious differentiation and subsequent hypertrophy compared to wild type cultures, suggesting that IGF-I potentiates and accelerates the myogenic program in satellite cells derived from these animals. Such a pattern should be reproduced in all other vertebrates expressing the transgene, and will lead to the production of animals that will be born without complication (animal size essentially normal at birth), and will have an increased mass of muscle for meat production in juvenile and adult stages of life. An illustration of the muscles of transgenic mice, compared with otherwise identical non-transgenic mice, is shown in Figure 5.

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

While the invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

What is claimed is:

1. A method of increasing vertebrate muscle mass and muscle strength, said method comprising administering a muscle enhancing dose of an isolated nucleic acid encoding Insulin-like Growth Factor I (IGF-I), or a modification or biologically active portion thereof, intramuscularly into a vertebrate, wherein said isolated nucleic acid is expressed in muscle cells, thereby increasing said muscle mass and said muscle strength in the muscle of said vertebrate.

5

2. The method of claim 1, wherein said vertebrate is selected from a group consisting of rat, mouse, cat, dog, horse, cow, pig, sheep, goat, fish, bird, and
10 human.

10

3. The method of claim 2, wherein said vertebrate is a human.

4. The method of claim 1, wherein said IGF-1 is of the same species as
said vertebrate.

15

5. The method of claim 1, wherein said isolated nucleic acid is contained within a virus vector.

6. The method of claim 5, wherein said muscle enhancing dose ranges from between about 10^{10} to about 10^{12} recombinant virus vector particles per gram of muscle.

20

7. An isolated nucleic acid comprising a vertebrate IGF-I coding region, or a modification or portion thereof, operably linked to a muscle specific promoter/regulatory region, wherein said IGF-I coding region is flanked on the 5' side

by an SV40 intron sequence and wherein said IGF-I coding region is flanked on the 3' end by an SV40 polyadenylation signal sequence.

8. The isolated nucleic acid of claim 7, wherein said muscle specific promoter/regulatory region is selected from a group consisting of the myosin light chain 1/3 promoter/enhancer, the skeletal α -actin promoter, the muscle creatine kinase promoter/enhancer and a muscle specific troponin promoter.

5
9. The method of claim 8, wherein said muscle specific troponin promoter is the fast troponin C promoter/enhancer.

10
10. The isolated nucleic acid of claim 8, wherein said muscle specific promoter/regulatory region is the myosin light chain 1/3 promoter/enhancer.

11. The isolated nucleic acid of claim 7, wherein said muscle specific promoter/regulatory region further comprises an enhancer element operably linked to the IGF-I coding region.

15
12. The isolated nucleic acid of claim 11, wherein said enhancer is the myosin light chain 1/3 enhancer.

13. A composition comprising a recombinant virus vector comprising said isolated nucleic acid of claim 12.

14. The composition of claim 13, wherein said recombinant virus vector is selected from the group consisting of an adeno-associated virus, an adenovirus and a
20 herpes simplex virus.

15. The composition of claim 14, wherein said recombinant virus vector is an adeno-associated virus.

16. A cell comprising the isolated nucleic acid of claim 7.

17. A cell comprising the recombinant virus vector of claim 15.

5 18. A kit for increasing muscle mass and muscle strength in a vertebrate, said kit comprising a muscle enhancing dose of the isolated nucleic acid encoding IGF-I of claim 7, wherein said isolated nucleic acid is expressed in vertebrate muscle cells, and wherein said kit further comprises an applicator for delivering said muscle enhancing dose, and instructions for the use of said kit.

10 19. A non-human transgenic vertebrate animal comprising an isolated nucleic acid encoding Insulin-like Growth Factor I (IGF-I), or a modification or biologically active portion thereof.

15 20. The non-human transgenic vertebrate animal of claim 19, wherein said IGF-1 is operably linked to a muscle specific promoter/regulatory sequence at the 5' end of said IGF-1 and a polyadenylation termination signal at the 3' end of said IGF-1.

20 21. The non-human transgenic vertebrate animal of claim 20, wherein said muscle specific promoter/regulatory sequence is selected from the group consisting of the myosin light chain 1/3 promoter/enhancer, the skeletal α -actin promoter, the muscle creatine kinase promoter/enhancer and a muscle specific troponin promoter.

22. The non-human transgenic vertebrate animal of claim 19 being selected from the group consisting of rat, mouse, cat, dog, horse, cow, pig, sheep, goat, fish, bird, and human.

5 23. The method of claim 1, further comprising administering to said vertebrate fibroblast growth factor or neurotropin.

1/6

FIG. IA


IGF-I rAAV Gene Construct

FIG.IB 1

2

3

4

IGF-I



FIG.IC

Actin



FIG.ID

RNA



2/6

PCT/US98/17428

FIG. 2A/i
Control

FIG. 2A/ii
+ IGF-I

SUBSTITUTE SHEET (RULE 26)

3/6

FIG. 2B




FIG. 3A
Muscle Mass
Tetanic Force
Specific Force




Fig. 4

5'- GGACGTACCAAAATGAGCGCACCTCCAATAAAGATAACACATCATGT
CGTCTTCACATCTCTTCTACCTGGCACTCTGCTGCTCACCTTACCAAGC
TCGGCCACAGCCGGACCAGAGACCCTTGCGGGGCTGAGCTGGTGGAC
GCTCTTCAGTCGTGTGGACCAAGGGGCTTTACTTCAACAAGGCCA
CAGGCTATGGCTCCAGCATTGGAGGGCACCACAGACGGCATTGTGG
ATGAGTGTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACT
GTGCTCCGCTGAAGCCTACAAAGTCAGCTCGTCCATCCGGGCCCAGC
GCCACACTGACATGCCAAGACTCAGAAGGAAGTACACTTGAAGAAC
CAAGTAGAGGAAGTGCAGGAAACAAGACCTACAGAATGTAGGAGGAG
CCTCCCGAGGAACAGAAAATGCCACGTCACCGCAAGATCCTTGCTGC
TTGAGCAACCTGCAAAACATCGGAACACACCTGCCAAATATCAATAATGA
GTTCAATACCATTTCAGAGATGGGCATTCCCTCAATGAAATACACAA
GTAAACATTCCGACATTGTCTTAGGAGTGGTTGTTAAAAAAA
CAAAAAACAAAAACAAAAACAAAAAAAGCTTGCACCTGCAAAAG
TGGTCCTGGCGTAGGGTAGATTGCTGTTAACCTTATCAATAACGTTCT
ATAGAGAATATATAAATATATATAATTATATCTCCTAGTCCCTGCCT
CTTAAGAGCCAAAATGCATGGGTGTTGAGACATTGGTTGCACCAA
ATTCCCTCTGAATTGGCTGCTGAAGCCGTTCAATTAGCAACTGTTA
TAGGTGGTTGATGAATGGTCCTTATCTCCATTCTCCTATGTAGCTTA
AGCCGCTTCCTCACAGAATCTAATACTCGTCTAGGCCATTAGCCCT
GCCCTTCTTAACATTCTGTATTGTTGAATTGGCCTCGAAAGCA
ATAGCAACTGGGTGGCCCACCCAAGTTAACGCC -3'

FIG. 5A
Wild Type 6 months

FIG. 5B
Tg MLC1/GF-1 6 months



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17428

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 325; 514/44; 536/23.1, 23.51; 800/8, 9, 13, 14, 15, 16, 17, 18, 19, 20

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	COLEMAN et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 19 May 1995, Vol. 270, No. 20, pages 12109-12116, entire document.	1-23
Y	LEE et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinology and Metabolism. August 1996, Vol. 81, No. 8, pages 2968-2975, entire document.	1-23

 Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 OCTOBER 1998

Date of mailing of the international search report

04 NOV 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile N . (703) 305-3230

Authorized officer

ANNE-MARIE BAKER, PH.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/17428

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WATERS et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 01 December 1996, Vol. 125, No. 11, pages 865-872, entire document.	1-23
Y	COTTERILL, A.M. The therapeutic potential of recombinant human insulin-like growth factor-I. Clinical Endocrinology. 1992, Vol. 37, pages 11-15, entire document.	1-23
Y	LANGE, D.J. et al. Recombinant human insulin-like growth factor-I in ALS: Description of a double-blind, placebo-controlled study. Neurology. October 1996, Vol. 47, No. 4, Suppl. 2, pages S93-S95, entire document.	1-23
Y	REISS et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl. Acad. Sci. USA. 06 August 1996, Vol. 93, No.16, pages 8630-8635, entire document.	1-23
Y	STEWART et al. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J. Biol. Chem. 10 May 1996, Vol. 271, No. 19, pages 11330-11338, entire document.	1-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17428

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 48/00; C07H 21/04; C12N 15/00, 15/11, 15/63, 15/85, 15/86

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/320.1, 325; 514/44; 536/23.1, 23.51; 800/8, 9, 13, 14, 15, 16, 17, 18, 19, 20

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS

STN (file: medicine)

search terms: insulin-like growth factor, IGF, muscle, myocyte, muscle(10n)strength, transgen?, mouse or mice, promoter, myosin(10n)promoter, actin(10n)promoter, creatine kinase(10n)promoter, troponin(10n)promoter

